AMPLITUDE-O

Definition

Cardiovascular outcomes for efpeglenatide in type 2 diabetes at high CV risk (Gerstein et al., NEJM 2021): a 27% relative reduction in three-point MACE. The drug was never marketed in the US, which is a reminder that trial success and availability are different questions.

AMPLITUDE-O trial deep-dive →

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.

Other terms under trial

• SURMOUNT-5
• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• AMPLITUDE-O trial deep-dive
• The full GLP-1 glossary (149 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers